SynAct Pharma AB has been approved for listing on Nasdaq Stockholm
Nasdaq Stockholm´s listing committee has today announced that it considers that SynAct Pharma AB (“SynAct” or the “Company”) meets the applicable listing requirements and that they will approve the application for admission to trading of the Company’s shares in Nasdaq Stockholm Main Market subject to customary conditions being met, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and the fulfilment of the distribution requirement for the Company’s shares. The first day of trading on Nasdaq Stockholm is expected to